NVCR News and Press, NovoCure Limited From 04/01/24

2024-04-01 17:08:57 ET Gainers: Zapata Computing  (ZPTA) +12% . Thoughtworks Holding ( TWKS ) +4% . Gain Therapeutics ( GANX ) +3% . Portillo's ( PTLO ) +3% . Vital Farms ( VITL ) +3% . Losers: Signature Bank ( OTC:SBN...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three mo...

2024-03-30 06:34:10 ET Shares of Novocure (NASDAQ: NVCR) jumped 18.3% this week, according to data from S&P Global Market Intelligence , after the company announced encouraging results from a phase 3 study of its Tumor Treating Fields (TTFields) therapy for treating brain me...

2024-03-27 22:55:50 ET Summary NovoCure’s METIS trial met its primary endpoint but missed key secondary outcomes, casting doubt on TTFields' efficacy in NSCLC. Despite hitting the primary endpoint, TTFields’ role in NSCLC treatment is questionable without significant...

2024-03-27 08:25:49 ET DENVER, Colo., Mar 27, 2024 ( 247marketnews.com )- Novocure (NASDAQ: NVCR ) announced, this morning, that the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for a...

2024-03-27 07:50:51 ET More on NovoCure NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript NovoCure Limited 2023 Q4 - Results - Earnings Call Presentation NovoCure: Stay Cautious Amid Positive Signs NovoCure Q4 2023 Earnings Preview NovoCure Tum...

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated with supportive care alone Novocure to host investor conference call at 8 a.m. EDT No...

2024-03-25 11:19:34 ET Oppenheimer argued on Monday that the S&P 500 ( SP500 ) is poised for a move higher when looking back at macro similarities from 1987 to 1990. The key takeaway from the '87-'90 road map was that the Fed’s first rate cut proceeded the top in market bread...

2024-03-24 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Exploratory subgroup analysis from INNOVATE-3 finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naïve patients treated with paclitaxel alone ...